nach oben

Seminars in Immunopathology

Erschienen in:

08.06.2017 | Review

Cellular and molecular pathways of structural damage in rheumatoid arthritis

verfasst von: Ulrike Harre, Georg Schett

Erschienen in: Seminars in Immunopathology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Structural damage of cartilage and bone tissue is a hallmark of rheumatoid arthritis (RA). The resulting joint destruction constitutes one of the major disease consequences for patients and creates a significant burden for the society. The main cells executing bone and cartilage degradation are osteoclasts and fibroblast-like synoviocytes, respectively. The function of both cell types is heavily influenced by the immune system. In the last decades, research has identified several mediators of structural damage, ranging from infiltrating immune cells and inflammatory cytokines to autoantibodies. These factors result in an inflammatory milieu in the affected joints which leads to an increased development and function of osteoclasts and the transformation of fibroblast-like synoviocytes towards a highly migratory and destructive phenotype. In addition, repair mechanisms mediated by osteoblasts and chondrocytes are strongly impaired by the presence of pro-inflammatory cytokines. This article will review the current knowledge on the mechanisms of joint inflammation and the destruction of bone and cartilage.

van de Sande MG, Baeten DL (2016) Immunopathology of synovitis: from histology to molecular pathways. Rheumatology (Oxford) 55:599–606CrossRef

Zerbini CA, et al (2016) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int

Teitelbaum SL (2011) The osteoclast and its unique cytoskeleton. Ann N Y Acad Sci 1240:14–17CrossRefPubMed

Takahashi N et al (2014) Vitamin D endocrine system and osteoclasts. Bonekey Rep 3:495CrossRefPubMedPubMedCentral

Nakahama K (2010) Cellular communications in bone homeostasis and repair. Cell Mol Life Sci 67:4001–4009CrossRefPubMed

Cohen SB et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299–1309CrossRefPubMed

Deodhar A et al (2010) Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 62:569–574CrossRef

Jarrett SJ et al (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54:1410–1414CrossRefPubMed

Takayanagi H (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med (Berl) 83:170–179CrossRef

10.

Nelson CA et al (2012) RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 20:1971–1982CrossRefPubMedPubMedCentral

11.

Crotti TN et al (2015) Osteoimmunology: major and costimulatory pathway expression associated with chronic inflammatory induced bone loss. J Immunol Res 2015:281287CrossRefPubMedPubMedCentral

12.

van Tuyl LH et al (2010) Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 69:1623–1628CrossRefPubMed

13.

Kong YY et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323CrossRefPubMed

14.

Akiyama T et al (2012) RANKL-RANK interaction in immune regulatory systems. World J Orthop 3:142–150CrossRefPubMedPubMedCentral

15.

Sato K et al (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682CrossRefPubMedPubMedCentral

16.

Takayanagi H et al (1997) A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 240:279–286CrossRefPubMed

17.

Danks L et al (2016) RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis 75:1187–1195CrossRefPubMed

18.

Hashizume M et al (2008) IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 47:1635–1640CrossRef

19.

Yeo L et al (2011) Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 70:2022–2028CrossRefPubMedPubMedCentral

20.

Meednu N et al (2016) Production of RANKL by memory B cells: a link between B cells and bone erosion in rheumatoid arthritis. Arthritis Rheumatol 68:805–816CrossRefPubMedPubMedCentral

21.

Li Y et al (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109:3839–3848CrossRefPubMedPubMedCentral

22.

Walsh NC et al (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 24:1572–1585CrossRefPubMed

23.

Braun T, Zwerina J (2011) Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther 13:235CrossRefPubMedPubMedCentral

24.

Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656–664CrossRefPubMedPubMedCentral

25.

Yao Z et al (2006) Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 281:11846–11855CrossRefPubMed

26.

Mori T et al (2011) IL-1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 23:701–712CrossRefPubMed

27.

Wong PK et al (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 54:158–168CrossRefPubMed

28.

Kotake S et al (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88–95CrossRefPubMed

29.

Amarasekara DS et al (2015) Bone loss triggered by the cytokine network in inflammatory autoimmune diseases. J Immunol Res 2015:832127CrossRefPubMedPubMedCentral

30.

Mateen S et al (2016) Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta 455:161–171CrossRefPubMed

31.

Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36:1118–1125CrossRefPubMed

32.

Jiang Y et al (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43:1001–1009CrossRefPubMed

33.

Kitami S et al (2010) IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells. Biochimie 92:398–404CrossRefPubMed

34.

Kotake S et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352CrossRefPubMedPubMedCentral

35.

Bax M et al (2014) The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. Semin Immunopathol 36:313–325CrossRefPubMed

36.

Baka Z et al (2012) Citrullination under physiological and pathological conditions. Joint Bone Spine 79:431–436CrossRefPubMed

37.

Toes RE, Huizinga TJ (2015) Update on autoantibodies to modified proteins. Curr Opin Rheumatol 27:262–267CrossRefPubMed

38.

Amara K et al (2013) Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 210:445–455CrossRefPubMedPubMedCentral

39.

Van Steendam K et al (2010) Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res Ther 12:R132CrossRefPubMedPubMedCentral

40.

Mathsson L et al (2006) Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther 8:R64CrossRefPubMedPubMedCentral

41.

Clavel C et al (2008) Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 58:678–688CrossRefPubMed

42.

Lu MC et al (2010) Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production. Arthritis Rheum 62:1213–1223CrossRefPubMed

43.

Harre U et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791–1802CrossRefPubMedPubMedCentral

44.

Krishnamurthy A et al (2016) Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis 75:721–729CrossRefPubMed

45.

Harre U et al (2012) Moonlighting osteoclasts as undertakers of apoptotic cells. Autoimmunity 45:612–619CrossRefPubMed

46.

Seeling M et al (2013) Inflammatory monocytes and Fcgamma receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A 110:10729–10734CrossRefPubMedPubMedCentral

47.

Harre U et al (2015) Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun 6:6651CrossRefPubMedPubMedCentral

48.

Arnold JN et al (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21–50CrossRefPubMed

49.

Bohm S et al (2012) The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 34:443–453CrossRefPubMed

50.

Scherer HU et al (2010) Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 62:1620–1629CrossRefPubMed

51.

Pfeifle R, et al (2016) Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol

52.

van der Woude D et al (2010) Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 69:1554–1561CrossRefPubMed

53.

Kokkonen H et al (2011) Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 13:R13CrossRefPubMedPubMedCentral

54.

Suwannalai P et al (2012) Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 64:1323–1328CrossRefPubMed

55.

Rombouts Y et al (2015) Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 74:234–241CrossRefPubMed

56.

Shi J et al (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 108:17372–17377CrossRefPubMedPubMedCentral

57.

Kleyer A et al (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73:854–860CrossRefPubMed

58.

Walsh NC, Gravallese EM (2010) Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233:301–312CrossRefPubMed

59.

Baum R, Gravallese EM (2016) Bone as a target organ in rheumatic disease: impact on osteoclasts and osteoblasts. Clin Rev Allergy Immunol 51:1–15CrossRefPubMed

60.

Harada S, Rodan GA (2003) Control of osteoblast function and regulation of bone mass. Nature 423:349–355CrossRefPubMed

61.

Gilbert L et al (2002) Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277:2695–2701CrossRefPubMed

62.

Kaneki H et al (2006) Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 281:4326–4333CrossRefPubMed

63.

Yeremenko N et al (2015) Tumor necrosis factor and interleukin-6 differentially regulate Dkk-1 in the inflamed arthritic joint. Arthritis Rheumatol 67:2071–2075CrossRefPubMed

64.

Wang SY et al (2011) Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 38:821–827CrossRefPubMed

65.

Glass DA 2nd et al (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751–764CrossRefPubMed

66.

Diarra D et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163CrossRefPubMed

67.

de Rooy DP et al (2013) Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis 72:769–775CrossRefPubMed

68.

Matzelle MM et al (2016) Inflammation in arthritis induces expression of BMP3, an inhibitor of bone formation. Scand J Rheumatol 45:379–383CrossRefPubMed

69.

Stashenko P et al (1987) Interleukin-1 beta is a potent inhibitor of bone formation in vitro. J Bone Miner Res 2:559–565CrossRefPubMed

70.

Shaw AT et al (2016) IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis. Arthritis Res Ther 18:104CrossRefPubMedPubMedCentral

71.

Bhattaram P, Chandrasekharan U (2016) The joint synovium: a critical determinant of articular cartilage fate in inflammatory joint diseases. Semin Cell Dev Biol

72.

Schonfeld C et al (2015) Fibroblasts as pathogenic cells in rheumatic inflammation. Z Rheumatol 74:33–38CrossRefPubMed

73.

Neumann E et al (2010) Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med 16:458–468CrossRefPubMed

74.

Linder S (2009) Invadosomes at a glance. J Cell Sci 122:3009–3013CrossRefPubMed

75.

Kim KW et al (2015) Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. Am J Pathol 185:3011–3024CrossRefPubMed

76.

Lefevre S et al (2009) Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 15:1414–1420CrossRefPubMedPubMedCentral

77.

Klein K et al (2012) Epigenetic contributions in the development of rheumatoid arthritis. Arthritis Res Ther 14:227CrossRefPubMedPubMedCentral

78.

Karouzakis E et al (2009) DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 60:3613–3622CrossRefPubMed

79.

Diermeier S et al (2014) TNFalpha signalling primes chromatin for NF-kappaB binding and induces rapid and widespread nucleosome repositioning. Genome Biol 15:536CrossRefPubMedPubMedCentral

80.

Sherwood JC et al (2014) Cellular and molecular mechanisms of cartilage damage and repair. Drug Discov Today 19:1172–1177CrossRefPubMed

Titel: Cellular and molecular pathways of structural damage in rheumatoid arthritis
verfasst von: Ulrike Harre
Georg Schett
Publikationsdatum: 08.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Seminars in Immunopathology / Ausgabe 4/2017
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-017-0634-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cellular and molecular pathways of structural damage in rheumatoid arthritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Cardiovascular risk in patients with rheumatoid arthritis

Comment on “Epigenetics in the pathogenesis of RA”

Selected cytokine pathways in rheumatoid arthritis

Arthritis models: usefulness and interpretation

The role of autoantibodies in the pathophysiology of rheumatoid arthritis

Future therapeutic targets in rheumatoid arthritis?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin